In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
The failure of Eyenovia's CHAPERONE study has seen the company’s stock value drop drastically as it considers options and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback